Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06132945 · ClinicalTrials.gov registry record · Phase 1
A Study of Cabozantinib and Nivolumab With Radiation Therapy for People With Renal Cell Carcinoma That Has Spread to the Brain
A Phase 1 study of Brain Metastases and Metastatic Renal Cell Carcinoma, sponsored by Memorial Sloan Kettering Cancer Center.
- Active
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
- 7
- Study locations
NCT06132945 is a Phase 1 study of Brain Metastases and Metastatic Renal Cell Carcinoma that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 2 participants, below the 213-participant average among 67 other Brain Metastases trials with a reported enrollment target (99% lower). The trial reports 7 study locations across 2 states.
The verdict
NCT06132945, a Phase 1 study of Brain Metastases and Metastatic Renal Cell Carcinoma, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
- 7
- Study locations
Study Summary
The purpose of this study is to find out whether the combination of cabozantinib, nivolumab, and radiation therapy is a safe and effective treatment that causes few or mild side effects in people with renal cell cancer that has spread to the brain. The researches will also look at how the study treatment affects the quality of life of participants. They will measure the quality of life by having participants complete questionnaires.
Conditions Studied
Interventions
- DRUG Cabozantinib
- RADIATION Stereotactic Radiosurgery (SRS)
- DEVICE Nivolumab
Study Locations (7)
New York
- Memorial Sloan Kettering Cancer Suffolk - Commack (All Protocol Activities) - Commack
- Memorial Sloan Kettering Westchester (All Protocol Activities) - Harrison
- Memorial Sloan Kettering Cancer Center (All Protocol Activities) - New York
- Memorial Sloan Kettering Nassau (All Protocol Activities) - Uniondale
New Jersey
- Memorial Sloan Kettering Basking Ridge (All Protocol Activities) - Basking Ridge
- Memorial Sloan Kettering Monmouth (All Protocol Activities) - Middletown
- Memorial Sloan Kettering Bergen (All Protocol Activities) - Montvale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2023-11-10 |
| Est. Completion | 2027-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06132945
The ClinicalTrials.gov registry entry for NCT06132945 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 213-participant average among 67 other Brain Metastases trials with a reported enrollment target (99% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Brain Metastases appearing as the primary indexed condition, and to 3 interventions - of which Cabozantinib is the first listed.
NCT06132945 reports 7 study locations spanning 2 distinct geographic areas - top geographies include New York, New Jersey.
Frequently Asked Questions
What is clinical trial NCT06132945 about?
NCT06132945 is a clinical study titled "A Study of Cabozantinib and Nivolumab With Radiation Therapy for People With Renal Cell Carcinoma That Has Spread to the Brain". The purpose of this study is to find out whether the combination of cabozantinib, nivolumab, and radiation therapy is a safe and effective treatment that causes few or mild side effects in people with renal cell cancer that has spread to the brain. The researches will also look at how the study trea...
What is the current status of trial NCT06132945?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2023-11-10. Estimated completion is 2027-11.
What conditions does trial NCT06132945 study?
This clinical trial studies the following conditions: Brain Metastases, Metastatic Renal Cell Carcinoma.
What interventions are being tested in trial NCT06132945?
The interventions under investigation include: Cabozantinib (DRUG), Stereotactic Radiosurgery (SRS) (RADIATION), Nivolumab (DEVICE).
Who is sponsoring clinical trial NCT06132945?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06132945 being conducted?
This trial has 7 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Brain Metastases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
18F-Fluciclovine PET Amino Acid Evaluation of Brain Metastasis Treated With Stereotactic Radiosurgery
RECRUITING · Phase 1
-
Assess Use of 18F-Fluciclovine for Patients With Large Brain Metastases Treated With Staged Stereotactic Radiosurgery
RECRUITING · Phase 1
-
Stereotactic Radiation & Abemaciclib in the Management of HR+/HER2- Breast Cancer Brain Metastases
RECRUITING · Phase 1
-
Delayed or Upfront Brain RAdiotherapy in Treatment naïve Lung Cancer Patients With Asymptomatic or Minimally Symptomatic Brain Metastases and ALK rEarrangements
RECRUITING · Phase 1
-
Phase I Study of Fractionated Stereotactic Radiation Therapy
RECRUITING · Phase 1
-
Personalized Radiotherapy for Individualized Treatment Strategies and Monitoring (PRISM)
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.